skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Clinical cancer research, 2019-07, Vol.25 (13), p.3753-3758 [Peer Reviewed Journal]

2019 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-18-4070 ;PMID: 30787022

Full text available

Citations Cited by
  • Title:
    FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
  • Author: Marcus, Leigh ; Lemery, Steven J ; Keegan, Patricia ; Pazdur, Richard
  • Is Part Of: Clinical cancer research, 2019-07, Vol.25 (13), p.3753-3758
  • Description: The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and for the treatment of unresectable or metastatic MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The FDA granted the approval based on an understanding of the biology of MSI-H/dMMR across different tumors along with the clinically important effects on overall response rate (ORR) observed in patients who were enrolled in 1 of 5 single-arm clinical trials. The ORR was 39.6% among 149 patients with 15 different tumor types (95% confidence interval, 31.7-47.9), with a 7% complete response rate. The duration of response ranged from 1.6+ months to 22.7+ months, with 78% of responses lasting ≥6 months. Overall, the adverse event profile of pembrolizumab was similar to the adverse event profile observed across prior trials that supported the approval of pembrolizumab in other indications. This approval of pembrolizumab is the first time that the FDA has approved a cancer treatment for an indication based on a common biomarker rather than the primary site of origin.
  • Publisher: United States
  • Language: English
  • Identifier: ISSN: 1078-0432
    EISSN: 1557-3265
    DOI: 10.1158/1078-0432.ccr-18-4070
    PMID: 30787022
  • Source: Geneva Foundation Free Medical Journals at publisher websites
    Alma/SFX Local Collection
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait